Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Jan 15;11(1):3-4.
doi: 10.5009/gnl16574.

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?

Chang Soo Eun  1
Affiliations
Editorial

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?

Chang Soo Eun. Gut Liver. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Lee HA, Suk JY, Choi SY, et al. Characteristics of pediatric inflammatory bowel disease in Korea: comparison with EUROKIDS data. Gut Liver. 2015;9:756–760. doi: 10.5009/gnl14338. - DOI - PMC - PubMed
    1. Kim MJ, Lee WY, Choe YH. Expression of TIM-3, human beta-defensin-2, and FOXP3 and correlation with disease activity in pediatric Crohn’s disease with infliximab therapy. Gut Liver. 2015;9:370–380. doi: 10.5009/gnl13408. - DOI - PMC - PubMed
    1. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol. 2014;11:243–255. doi: 10.1038/nrgastro.2013.253. - DOI - PubMed
    1. Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol. 2011;106:674–684. doi: 10.1038/ajg.2011.60. - DOI - PubMed
    1. Ben-Horin S, Kopylov U, Chowers Y. Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev. 2014;13:24–30. doi: 10.1016/j.autrev.2013.06.002. - DOI - PubMed

LinkOut - more resources